FT
SUPN icon

Fiduciary Trust’s Supernus Pharmaceuticals SUPN Stock Holding History

Fiduciary Trust’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$761K Hold
14,714
– – 0.01% 472
2025
Q4 		$731K Buy
14,714
+661
+5% +$32.1K 0.01% 478
2025
Q3 		$672K Sell
14,053
-1,705
-11% -$68.7K 0.01% 494
2025
Q2 		$497K Buy
15,758
+5
+0% +$160 0.01% 535
2025
Q1 		$516K Buy
+15,753
New +$558K 0.01% 515

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fiduciary Trust's SUPN Position: Q1 2026 in Review

Fiduciary Trust held its Supernus Pharmaceuticals (SUPN) position steady in Q1 2026 at 14,714 shares worth $761K. The position accounts for 0.01% of the portfolio, ranked #472.

Fiduciary Trust first reported a position in SUPN in Q1 2025 and has held it in 5 quarters since. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

  • Fiduciary Trust held 14,714 shares of Supernus Pharmaceuticals worth $761K as of Q1 2026.
  • Fiduciary Trust left its Supernus Pharmaceuticals share count unchanged in Q1 2026.
  • Supernus Pharmaceuticals made up 0.01% of Fiduciary Trust's portfolio in Q1 2026, its #472 holding.
  • Fiduciary Trust first reported a position in Supernus Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Fiduciary Trust's 13F filing for Q1 2026, filed 15 May 2026.